Cash, cash equivalents and marketable securities were approximately $563.3M as of September 30. “With a strong balance sheet, we continue to make great progress on our cardiac and skeletal muscle programs,” said CEO Kevin Koch. “Planning for success in GRAND CANYON, we are building the commercial infrastructure to support a potential launch of sevasemten in Becker. We recently initiated clinical development of EDG-15400, our new clinical candidate targeting heart failure and we’re actively developing Phase 3 trial designs in HCM and Duchenne, while continuing to advance our pipeline through innovative R&D.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics price target raised to $33 from $30 at JPMorgan
- Edgewise Therapeutics Advances with Phase 1 Study of EDG-15400
- Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study
- Edgewise Therapeutics Advances EDG-7500 Study for Hypertrophic Cardiomyopathy
- Edgewise Therapeutics’ EDG-7500 Study: A Potential Game Changer for Renal Impairment Treatment?